JP2023067881A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023067881A5 JP2023067881A5 JP2023021625A JP2023021625A JP2023067881A5 JP 2023067881 A5 JP2023067881 A5 JP 2023067881A5 JP 2023021625 A JP2023021625 A JP 2023021625A JP 2023021625 A JP2023021625 A JP 2023021625A JP 2023067881 A5 JP2023067881 A5 JP 2023067881A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound according
- salt
- formula
- edema
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025107413A JP2025148369A (ja) | 2020-02-13 | 2025-06-25 | 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20157259 | 2020-02-13 | ||
| EP20157259.1 | 2020-02-13 | ||
| JP2022514811A JP7230277B2 (ja) | 2020-02-13 | 2021-02-11 | 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体 |
| PCT/EP2021/053286 WO2021160718A1 (en) | 2020-02-13 | 2021-02-11 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514811A Division JP7230277B2 (ja) | 2020-02-13 | 2021-02-11 | 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025107413A Division JP2025148369A (ja) | 2020-02-13 | 2025-06-25 | 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023067881A JP2023067881A (ja) | 2023-05-16 |
| JP2023067881A5 true JP2023067881A5 (https=) | 2024-02-20 |
| JP7703587B2 JP7703587B2 (ja) | 2025-07-07 |
Family
ID=69591572
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514811A Active JP7230277B2 (ja) | 2020-02-13 | 2021-02-11 | 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体 |
| JP2023021625A Active JP7703587B2 (ja) | 2020-02-13 | 2023-02-15 | 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体 |
| JP2025107413A Pending JP2025148369A (ja) | 2020-02-13 | 2025-06-25 | 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514811A Active JP7230277B2 (ja) | 2020-02-13 | 2021-02-11 | 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025107413A Pending JP2025148369A (ja) | 2020-02-13 | 2025-06-25 | 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11760745B2 (https=) |
| EP (1) | EP4103562A1 (https=) |
| JP (3) | JP7230277B2 (https=) |
| KR (1) | KR20220141333A (https=) |
| CN (2) | CN115052873A (https=) |
| AR (2) | AR121341A1 (https=) |
| AU (1) | AU2021218952A1 (https=) |
| BR (1) | BR112022013979A2 (https=) |
| CA (1) | CA3168690A1 (https=) |
| CL (2) | CL2022002101A1 (https=) |
| CO (1) | CO2022011254A2 (https=) |
| CR (2) | CR20250167A (https=) |
| DO (2) | DOP2022000157A (https=) |
| EC (1) | ECSP22062410A (https=) |
| IL (2) | IL320007A (https=) |
| JO (1) | JOP20220186A1 (https=) |
| MX (3) | MX2022009941A (https=) |
| PE (2) | PE20221591A1 (https=) |
| SA (1) | SA522440127B1 (https=) |
| TW (2) | TWI873290B (https=) |
| WO (1) | WO2021160718A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112839711A (zh) | 2018-10-10 | 2021-05-25 | 勃林格殷格翰国际有限公司 | 作为血浆激肽释放酶抑制剂的苯基四唑衍生物 |
| TW202144331A (zh) * | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| TWI873290B (zh) * | 2020-02-13 | 2025-02-21 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| WO2025001956A1 (zh) * | 2023-06-30 | 2025-01-02 | 远森制药（杭州）有限公司 | 杂芳族甲酰胺类化合物及其在医药上的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| DE10207037A1 (de) | 2002-02-20 | 2003-08-28 | Bayer Cropscience Gmbh | 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| DE10230012A1 (de) * | 2002-07-04 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 5,6-Dihydro-4H-imidazo[4,5,1-ij]chinoline,ihre Herstellung und ihre Verwendung als Arzneimittel |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| JP2005089362A (ja) | 2003-09-17 | 2005-04-07 | Sumitomo Chemical Co Ltd | アリールピラゾリン化合物及びその用途 |
| EP2259679A4 (en) | 2008-01-31 | 2011-09-14 | Joslin Diabetes Ct | METHODS OF TREATING KALLIKREIN RELATED DISORDERS |
| ES2674745T3 (es) * | 2010-02-11 | 2018-07-03 | Bristol-Myers Squibb Company | Macrociclos como inhibidores del factor XIa |
| EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| US20140378474A1 (en) | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| MY174018A (en) | 2013-05-23 | 2020-03-04 | Kalvista Pharmaceuticals Ltd | Heterocyclic derivates |
| WO2017001926A2 (en) | 2015-07-01 | 2017-01-05 | Lifesci Pharmaceuticals, Inc | Therapeutic inhibitory compounds |
| JP6855477B2 (ja) | 2015-10-27 | 2021-04-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体 |
| WO2017072020A1 (en) | 2015-10-27 | 2017-05-04 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| IL263235B (en) | 2016-05-31 | 2022-07-01 | Kalvista Pharmaceuticals Ltd | History of pyrazoles as plasma kallikrein inhibitors |
| CN110022875A (zh) | 2016-07-11 | 2019-07-16 | 莱福斯希医药公司 | 治疗性抑制化合物 |
| JP7175914B2 (ja) | 2017-04-21 | 2022-11-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害剤としてのヘテロアリールカルボキサミド誘導体 |
| JP7064512B2 (ja) * | 2017-05-17 | 2022-05-10 | デナリ セラピューティクス インコーポレイテッド | キナーゼ阻害剤およびその使用 |
| US10695334B2 (en) | 2018-08-16 | 2020-06-30 | Boehringer Ingelheim International Gmbh | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors |
| EP4031547B1 (en) | 2019-09-18 | 2024-07-17 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof |
| TWI873290B (zh) | 2020-02-13 | 2025-02-21 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| TW202144331A (zh) | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
-
2021
- 2021-02-09 TW TW110104875A patent/TWI873290B/zh active
- 2021-02-09 TW TW114103224A patent/TW202535863A/zh unknown
- 2021-02-11 JP JP2022514811A patent/JP7230277B2/ja active Active
- 2021-02-11 JO JOP/2022/0186A patent/JOP20220186A1/ar unknown
- 2021-02-11 IL IL320007A patent/IL320007A/en unknown
- 2021-02-11 PE PE2022001696A patent/PE20221591A1/es unknown
- 2021-02-11 CA CA3168690A patent/CA3168690A1/en active Pending
- 2021-02-11 CR CR20250167A patent/CR20250167A/es unknown
- 2021-02-11 KR KR1020227031639A patent/KR20220141333A/ko active Pending
- 2021-02-11 MX MX2022009941A patent/MX2022009941A/es unknown
- 2021-02-11 CR CR20220382A patent/CR20220382A/es unknown
- 2021-02-11 BR BR112022013979A patent/BR112022013979A2/pt unknown
- 2021-02-11 CN CN202180011395.3A patent/CN115052873A/zh active Pending
- 2021-02-11 CN CN202310088017.6A patent/CN116120287B/zh active Active
- 2021-02-11 AU AU2021218952A patent/AU2021218952A1/en active Pending
- 2021-02-11 WO PCT/EP2021/053286 patent/WO2021160718A1/en not_active Ceased
- 2021-02-11 IL IL295125A patent/IL295125B2/en unknown
- 2021-02-11 EP EP21706489.8A patent/EP4103562A1/en active Pending
- 2021-02-11 US US17/173,213 patent/US11760745B2/en active Active
- 2021-02-11 PE PE2023001617A patent/PE20231985A1/es unknown
- 2021-02-12 AR ARP210100385A patent/AR121341A1/es unknown
-
2022
- 2022-08-03 DO DO2022000157A patent/DOP2022000157A/es unknown
- 2022-08-04 CL CL2022002101A patent/CL2022002101A1/es unknown
- 2022-08-10 EC ECSENADI202262410A patent/ECSP22062410A/es unknown
- 2022-08-10 CO CONC2022/0011254A patent/CO2022011254A2/es unknown
- 2022-08-11 SA SA522440127A patent/SA522440127B1/ar unknown
- 2022-08-12 MX MX2025013436A patent/MX2025013436A/es unknown
- 2022-08-12 MX MX2025013435A patent/MX2025013435A/es unknown
-
2023
- 2023-02-15 JP JP2023021625A patent/JP7703587B2/ja active Active
- 2023-04-28 CL CL2023001244A patent/CL2023001244A1/es unknown
- 2023-08-25 US US18/455,865 patent/US12479827B2/en active Active
- 2023-09-14 DO DO2023000195A patent/DOP2023000195A/es unknown
- 2023-09-18 US US18/468,885 patent/US20240076286A1/en active Pending
- 2023-11-17 AR ARP230103113A patent/AR131110A2/es unknown
-
2025
- 2025-06-25 JP JP2025107413A patent/JP2025148369A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023067881A5 (https=) | ||
| AU2022270115B2 (en) | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
| JP7566889B2 (ja) | Ｉｌ－１７ａモジュレーターおよびその使用 | |
| JP6269862B2 (ja) | 三環性スピロ化合物 | |
| JP2011509309A5 (https=) | ||
| JP2022081661A5 (https=) | ||
| JPH01283220A (ja) | 血圧降下増強剤 | |
| CN115175905A (zh) | Zeste增强子同源物2抑制剂及其用途 | |
| JPH07502487A (ja) | 血糖低下性チアゾリジンジオンとその中間体 | |
| JP2020517619A5 (https=) | ||
| JP7338711B2 (ja) | Ｄｐアンタゴニスト | |
| CA2881260C (en) | Crystalline forms of dihydropyrimidine derivatives | |
| KR100292928B1 (ko) | 치환된헥사하이드로벤조페난트리딘 | |
| JP2024099528A5 (https=) | ||
| TW200526205A (en) | Nitrogen-containing heterocyclic compound, and medicine containing such compound as effective ingredient | |
| JP2002527506A (ja) | アセチルコリン受容体拮抗薬としてのエピバチジンアナログ | |
| WO2022033303A1 (zh) | 苄胺类衍生物及其制备方法与用途 | |
| CA3182610C (en) | 2-oxo-oxazolidine-5-carboxamides as nav1.8 inhibitors | |
| RU2007134267A (ru) | Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний | |
| JPWO2020207414A5 (https=) | ||
| CA3182610A1 (en) | 2-oxo-oxazolidine-5-carboxamides as nav1.8 inhibitors | |
| JPWO2022069509A5 (https=) | ||
| EA050718B1 (ru) | Модуляторы рецепторов ccr6 | |
| JP2001508399A (ja) | ５―ｈｔレセプターアンタゴニストとしてのインドール誘導体 | |
| JPS6222757A (ja) | 置換アニリノ−２−ピロリン誘導体 |